D. Dhuyvetter

发表

Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus.

J. Vlach, F. Pauwels, E. Arnoult, 2016, Journal of medicinal chemistry.

2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.

V. Pande, F. Pauwels, T. Jonckers, 2018, Journal of medicinal chemistry.

Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.

M. Mercken, T. Jacobs, L. Dillen, 2013, Journal of Alzheimer's disease : JAD.

JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate.

D. Moechars, K. Kusakabe, L. Leclercq, 2021, Journal of medicinal chemistry.

Direct nose to brain delivery of small molecules: critical analysis of data from a standardized in vivo screening model in rats

R. Vreeken, Frederik J. R. Rombouts, A. Bottelbergs, 2020, Drug delivery.

Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.

F. Pauwels, T. Jonckers, E. Arnoult, 2017, Journal of medicinal chemistry.

Design and synthesis of a novel series of cyanoindole derivatives as potent γ-secretase modulators.

G. Macdonald, M. Mercken, S. Samanta, 2019, Bioorganic & medicinal chemistry letters.

BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System

K. Blennow, M. Mercken, H. Zetterberg, 2012, PloS one.

Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests

T. Jacobs, B. Van Broeck, T. Erkens, 2016, Journal of Alzheimer's disease : JAD.

Echocardiographic and hemodynamic indices of myocardial contractility simultaneously evaluated in telemetered beagle dogs: A HESI-sponsored cross-company evaluation.

Eric I. Rossman, Jennifer B Pierson, N. Polissar, 2020, Journal of pharmacological and toxicological methods.

Trifluoromethyl Dihydrothiazine‐Based β‐Secretase (BACE1) Inhibitors with Robust Central β‐Amyloid Reduction and Minimal Covalent Binding Burden

K. Kusakabe, Shinji Suzuki, Y. Kido, 2019, ChemMedChem.

A translational assessment of preclinical versus clinical tools for the measurement of cardiac contractility: comparison of LV dP/dt(max) with echocardiography in telemetry implanted beagle dogs.

H. Geys, F. Cools, D. Gallacher, 2014, Journal of pharmacological and toxicological methods.

Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.

Michiel Van Gool, G. Macdonald, D. Moechars, 2018, Journal of medicinal chemistry.

Discovery of an Extremely Potent Thiazine-Based β-Secretase (BACE1) Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose.

K. Kusakabe, Shinji Suzuki, N. Asada, 2019, Journal of medicinal chemistry.

Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization.

Kenji Nakahara, Takahiko Yamamoto, K. Kusakabe, 2018, Journal of medicinal chemistry.

Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.

K. Kusakabe, Y. Kido, T. Fukushima, 2018, Journal of medicinal chemistry.